Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | NAMPT | P43490 | 13/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092936 | 1.00 | DRD2 (0.56) | DRD2DRD3NAMPTSMN1; SMN2CYP3A4 | |
| SCHEMBL6162066 | 0.94 | SMN1; SMN2 (0.53) | DRD2DRD3NAMPTSMN1; SMN2CYP3A4 | |
| SCHEMBL3077271 | 0.88 | NAMPT (0.64) | NAMPTSMN1; SMN2CYP3A4CYP2C9HDAC3 | |
| SCHEMBL3077273 | 0.88 | NAMPT (0.64) | NAMPTSMN1; SMN2CYP3A4CYP2C9HDAC3 | |
| SCHEMBL6268994 | 0.87 | DRD3 (0.53) | DRD2DRD3NAMPTCYP3A4CYP2C9 | |
| SCHEMBL6268991 | 0.87 | DRD3 (0.53) | DRD2DRD3NAMPTCYP3A4CYP2C9 | |
| SCHEMBL3082741 | 0.82 | NAMPT (0.57) | NAMPTSMN1; SMN2CYP3A4CYP2C9HDAC3 | |
| SCHEMBL3080174 | 0.82 | NAMPT (0.57) | NAMPTSMN1; SMN2CYP3A4CYP2C9HDAC3 | |
| SCHEMBL6266296 | 0.79 | DRD3 (0.72) | DRD2DRD3NAMPTCYP3A4CYP2C9 | |
| SCHEMBL6266293 | 0.79 | DRD3 (0.72) | DRD2DRD3NAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | DRD2 4023/4885DRD3 4289/4885NAMPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.